SAN DIEGO — A new analysis of matched cohorts with three years of follow-up suggests that patients with obesity and diabetes face a significantly lower risk of atrial fibrillation (AF) recurrence after ablation when treated with a glucagon-like peptide 1 (GLP-1) receptor agonist compared to other diabetes medications.
Although the study was retrospective, it included data from over 2,500 patients who were taking either a GLP-1 receptor agonist or one of two comparator drugs, according to Dr. Varun Sundaram, section chief of Advanced Heart Failure at the Louis Stokes Cleveland Veterans Affairs (VA) Medical Center.
